Drug Information

Drug General Information
Drug ID
D02QDQ
Former ID
DIB012210
Drug Name
QAX-576
Synonyms
IL-13 modulator (intravenous), Novartis
Indication Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] Phase 2 [523308]
Company
Novartis AG
Target and Pathway
Target(s) Interleukin-13 Target Info Modulator [532959]
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Fc epsilon RI signaling pathway
Measles
Asthma
Inflammatory bowel disease (IBD)
NetPath Pathway IL9 Signaling Pathway
TCR Signaling Pathway
IL2 Signaling Pathway
Leptin Signaling Pathway
TSLP Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database Glucocorticoid receptor regulatory network
IL12 signaling mediated by STAT4
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
WikiPathways SIDS Susceptibility Pathways
Cytokines and Inflammatory Response
Allograft Rejection
References
Ref 523308ClinicalTrials.gov (NCT01266135) Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
Ref 532959Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.